Oncology Med Begins Servicing New Multiple Year Contract With Large Physician Owned Surgery Center in Pittsburgh
10 November 2008 - 3:30PM
Marketwired
Oncology Med, Inc. (PINKSHEETS: ONCO), a Pittsburgh based cancer
treatment solutions group, announced today that it has begun
providing prostate cancer brachytherapy treatment services under a
new multiple year exclusive contract with Southwestern Ambulatory
Surgery Center; a physician owned surgery center being managed by
Titan Healthcare, one of the largest surgery center management
companies in the United States. This exclusive multi-year contract
will have Oncology Med providing physics and full turnkey prostate
cancer brachytherapy services, equipment, staff, and radionuclide
seed management to the surgery center and affiliated radiation
oncologists.
According to William Walker, Ph.D., Oncology Med's CEO and
founder, "We are continuing to expand our footprint in the
treatment of prostate cancer in the ambulatory surgery center
market because it is customer friendly to the patients and
physicians, a very viable and excepted treatment for the cure of
prostate cancer, has a lower cost to the healthcare market than
traditional hospital programs, and is a solid revenue generator for
our company. We will continue to aggressively seek out new clients
and contracted sites for our turnkey prostate cancer program for
the simple reason that it is a win/win for everyone; the patients
who seek minimally invasive cures for their cancer and ASCs who
seek low cost healthcare programs with good revenue margins."
"We are proud of our progress in securing new ambulatory surgery
center programs as well as hospital based cancer treatment programs
for low dose (LDR) and high dose (HDR) radiation treatment for
prostate and breast cancer, " added Jack Sloan, Vice President of
Business Development. "Not only are they great revenue sources for
our company, but these programs give us great pride in that we are
able to provide such a high quality of healthcare services for
patients through our contracted facilities to enable them a
minimally invasive, curative treatment for their cancers with a
lower cost of delivery."
LDR, or low dose radiation, treatment for prostate cancer is the
minimally invasive insertion of small radioactive seeds into the
prostate for the treatment of prostate cancer. The patient spends a
limited time in an outpatient setting, generally 3-5 hrs, and is
sent home the same day after treatment. In some cases, the patient
may receive some additional external beam radiation for 3-5 weeks
thereafter on an outpatient basis to ensure that all cancerous
areas including marginal areas around the prostate have been
thoroughly treated to eradicate the cancer.
"Our ambulatory surgery center (ASC) prostate brachytherapy
programs have been both clinically and financially successful for
Oncology Med mainly due to our speed of implementation after
contract execution and clinically excellent services provided to
the surgery centers and physicians," Sloan continued.
"In addition to our LDR and HDR clinical programs, our
consultation services for initiation of new programs and
particularly in the area of securing new and amended radiation
licenses relieves our contracted facilities of the headaches of
dealing with these issues alone," Walker added. "In this new era of
Nuclear Regulatory Commission (NRC) regulation changes and those
states which have expanded their own regulatory programs, having a
partner like Oncology Med who is on top of all the regulatory
issues assisting with making this a smooth process for obtaining or
expanding a radiation license is crucial," he concluded.
Oncology Med continues to expand and provide extensive
consultation services for new and expanded cancer center
construction, certification, and credentialing processes for Joint
Commission, as well as complete turnkey programs for continuation
or implementation of radiation treatment programs for ambulatory
surgery centers, radiation oncologists, urologists, and
hospitals.
All inquiries for Oncology Med's programs and services should be
made to its administrative offices at: Oncology Med, Inc., 11928
Ropp Lane, Lovettsville, VA 20180. Phone: (540) 822-5161
About Oncology Med, Inc.
Oncology Med is a public company engaged in the fulfillment of
services related to the treatment of various cancers. It currently
provides analysis and design of radiation treatment plans in order
for radiation oncologists to administer radiation treatments to
cancer patients. Current services facilitate radiation treatment
programs ranging from external beam radiation to more advanced
radiation treatment technologies.
More information about Oncology Med, Inc. can be found at
www.oncologymed.com.
NOTE: This press release may contain "forward-looking
statements." In some cases, you can identify forward-looking
statements by terminology such as "may," "will," "should," "could,"
"expects," "plans," "intends," "anticipates," "believes,"
"estimates," "predicts," "potential," "continue" or the negative of
such terms and other comparable terminology. These forward-looking
statements include, without limitation, statements about our market
opportunity, our strategies, competition, expected activities and
expenditures as we pursue our business plan, and the adequacy of
our available cash resources. Although we believe that the
expectations reflected in any forward-looking statements are
reasonable, we cannot guarantee future results, levels of activity,
performance or achievements. Actual results may differ materially
from the predictions discussed in these forward-looking statements.
Changes in the circumstances upon which we base our predictions
and/or forward-looking statements could materially affect our
actual results.
For information, please contact: Oncology Med, Inc. (540)
822-5161 Email Contact
Bellatora (PK) (USOTC:ECGR)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Bellatora (PK) (USOTC:ECGR)
Historical Stock Chart
Von Mai 2023 bis Mai 2024